TICKERNERD
Menu
ABSIABSIHealthcare · Biotechnology

ABSI Stock Forecast: Absci Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$9.55
+2.91% on the day

The 10 Wall Street analysts covering Absci Corp. hold a median 12-month price target of $14 — +46.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.6B
Ticker Nerd rank
35 / 100
Median analyst target
$14
Analysts covering
10
Total return, dividends reinvested
1W
+4.0%
1M
+14.8%
YTD
+173.6%
1Y
+273.0%
From 52W high
−17.8%
From 52W low
+315.2%
$2
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Absci Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Growth
53
Accruals
52
Issuance
48
Revisions
42
Size
39
Value
38
Volatility
19
Quality
19

Momentum (91): The shares have been drifting up relative to others.

Quality (19): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Oct 25Jan 26Apr 26Jul 26ABSIHigh $17Median $14Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $10Median $14High $17

The green dot is the last close — the median target sits +46.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026BTIGReiteratesBuy$13
12 Aug 2026NeedhamReiteratesBuy$11
2 July 2026Truist SecuritiesMaintainsBuy$11 → $17
2 July 2026Truist SecuritiesMaintainsBuy—
25 June 2026HC Wainwright & Co.MaintainsBuy—
25 June 2026HC Wainwright & Co.MaintainsBuy$8.00 → $16
24 June 2026BTIGMaintainsBuy—
24 June 2026NeedhamReiteratesBuy—
15 June 2026GuggenheimMaintainsBuy—
4 June 2026Leerink PartnersInitiatesOutperform—
28 May 2026BTIGInitiatesBuy—
8 May 2026Truist SecuritiesMaintainsBuy—
30 Mar 2026NeedhamReiteratesBuy—
25 Mar 2026NeedhamReiteratesBuy—
18 Mar 2026NeedhamReiteratesBuy—
18 Dec 2025HC Wainwright & Co.MaintainsBuy—
12 Dec 2025NeedhamReiteratesBuy—
13 Nov 2025NeedhamMaintainsBuy—
2 Oct 2025JP MorganInitiatesOverweight—
18 Aug 2025Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ABSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Absci Corp. (ABSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.4×

Cheaper than 93% of US stocks

Price / sales
1049.9×

Cheaper than 1% of US stocks

Price / book
6.7×

Cheaper than 16% of US stocks

EV / EBITDA
−12.1×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−46.4%

Higher than 6% of US stocks

Earnings growth (YoY)
−81.8%

Higher than 4% of US stocks

Gross margin
—
Operating margin
−10741.5%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−57.7%

Higher than 19% of US stocks

Return on assets
−34.1%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ABSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABSIAbsci Corp.$1.6B
35
MAZEMaze Therapeutics, Inc.$1.6B
19
FBRXForte Biosciences, Inc.$1.6B
34
VIRVir Biotechnology, Inc.$1.6B
93
XERSXeris Biopharma Holdings, Inc.$1.6B
86
INVAInnoviva, Inc.$1.6B
87
BCAXBicara Therapeutics, Inc.$1.6B
50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Absci Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABSI news & analysis

AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next

24/7 Wall Street · 18 Aug 2026neutral

On August 14, 2026, Advanced Micro Devices filed its first-ever 13F, disclosing a $1.31 billion equity portfolio concentrated in just six positions. The filing reveals AMD's largest investments and where the company expects AI demand to land next.

Why it matters — An Absci Corp. watcher would care because AMD's disclosed portfolio and AI demand outlook could signal which AI-related companies and sectors may see increased investment and demand.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Zacks Investment Research · 17 Aug 2026positive

Zacks Investment Research highlighted ABSI among four AI-powered drug discovery stocks that use AI platforms to transform drug discovery while advancing proprietary clinical pipelines. The article positions these companies as ones to watch as AI reshapes the pharma industry.

Why it matters — This item is directly relevant to ABSI watchers because it calls attention to the company's AI-driven drug discovery platform and clinical pipeline within a favorable industry trend.

Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Absci Corporation's Q2 2026 earnings call transcript was published by Seeking Alpha. The transcript documents the company's second-quarter 2026 earnings discussion.

Why it matters — A transcript of the quarterly earnings call offers Absci watchers a full record of management's commentary on the company's latest financial and operational results.

Absci Q2 Earnings Call Highlights

MarketBeat · 11 Aug 2026positive

Absci reported progress on ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for endometriosis development. The company also reported a larger cash balance following a June equity offering and a strategic investment from Eli Lilly.

Why it matters — The clinical progress on ABS-201 and the strengthened cash position from the equity offering and Eli Lilly investment are key factors for Absci watchers tracking the company's pipeline and financial runway.

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

GlobeNewsWire · 11 Aug 2026positive

Absci Corporation reported its second quarter 2026 financial and operating results, announcing positive interim Phase 1 data from the HEADLINE trial of ABS-201. The company also completed a $100 million underwritten offering, including a $40 million strategic investment from Eli Lilly & Company, with cash and marketable securities now sufficient to fund operations into the second half of 2028.

Why it matters — Absci watchers would care because the company reported encouraging clinical trial data for its lead candidate ABS-201 and secured additional funding and strategic backing from Eli Lilly, extending its cash runway into 2028.

FAQ

Frequently asked questions about ABSI stock

What is the ABSI stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Absci Corp. have a median 12-month price target of $14, with estimates ranging from $10 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABSI stock a buy right now?

Of the 10 analysts covering Absci Corp., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Absci Corp. 35 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABSI?

As at 22 Aug 2026, Absci Corp. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will ABSI stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +46.6% from the last close, and Ticker Nerd's factor model ranks Absci Corp. 35 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABSI stock forecast for 2030?

No analyst covering Absci Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $17 over the next 12 months.

How has ABSI stock performed over the past year?

Absci Corp. returned +273.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Absci Corp. do?

Absci Corporation is a clinical-stage biopharmaceutical company that specializes in using generative artificial intelligence to design and create biologic drugs. The company operates a data-first drug creation platform that integrates AI models with scalable wet lab technologies to discover, optimize, and produce therapeutic proteins and antibodies.

What is the latest news on ABSI?

The most recent item we track (24/7 Wall Street, 18 Aug 2026): "AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next". On August 14, 2026, Advanced Micro Devices filed its first-ever 13F, disclosing a $1.31 billion equity portfolio concentrated in just six positions. The filing reveals AMD's largest investments and where the company expects AI demand to land next.

Company

About Absci Corp.

Absci Corporation is a clinical-stage biopharmaceutical company that specializes in using generative artificial intelligence to design and create biologic drugs. The company operates a data-first drug creation platform that integrates AI models with scalable wet lab technologies to discover, optimize, and produce therapeutic proteins and antibodies. Absci’s integrated platform is used to identify novel drug targets, generate and engineer therapeutic candidates, and develop production cell lines in a unified process, aiming to streamline early-stage discovery and development workflows for biologics. Its technology leverages synthetic biology and high-throughput experimentation to predict, design, build, and screen large libraries of biologic drug candidates for partners in the biopharmaceutical industry. Absci focuses today on advancing AI-designed antibody therapeutics and other biologics across multiple disease areas, collaborating with pharmaceutical and biotechnology companies globally. Founded in 2011 and headquartered in Vancouver, Washington, Absci plays a specialized role at the intersection of biotechnology, artificial intelligence, and drug discovery.

CEO Mr. Sean McClain · 140 employees · United States · https://www.absci.com